Will the Medicare ACCESS Model Spark the Next Health Tech Gold Rush?
Why It Matters
ACCESS creates a $70 million‑plus reimbursement pipeline that could redefine digital‑health business models, but firms must overcome senior usability and payment challenges to capture the opportunity.
Key Takeaways
- •Medicare ACCESS will reimburse digital health tools for 70M beneficiaries.
- •Companies must adapt to lower health and tech literacy of seniors.
- •Physician endorsement and stronger evidence will drive product adoption.
- •Payment rates may not cover costs, deterring some firms.
- •AI could help with language translation and literacy testing.
Summary
The Health Affairs podcast introduces Medicare’s new ACCESS model, launching in July 2026. ACCESS—Advancing Chronic Care with Effective Scalable Solutions—will allow Medicare beneficiaries and their physicians to claim reimbursement for digital health products such as mobile disease‑management apps and wearable sensors, targeting chronic conditions like cardiovascular disease, diabetes, and hypertension.
The model opens a 70‑million‑person market that previously relied on corporate wellness contracts. Rundle explains that firms must shift from a business‑to‑business to a hybrid business‑to‑patient/physician approach, providing robust clinical evidence to win physician endorsement. Payment rates remain a concern; early adopters like OMAD and Hinge Health declined participation, citing insufficient reimbursement to cover evidence‑based care.
Rundle highlights two systemic hurdles: lower health and digital literacy among seniors, and the need for products to be linguistically and cognitively accessible. He notes AI’s promise for real‑time translation and scalable literacy testing, potentially easing these barriers. The discussion underscores that success hinges on designing senior‑friendly interfaces and proving outcomes within the program’s ten‑year pilot window.
If companies can meet these demands, the ACCESS model could trigger a digital‑health gold rush, reshaping revenue streams and accelerating Medicare spending growth. Conversely, failure to align product design, evidence, and reimbursement could stall adoption, leaving the market fragmented and limiting the promised improvements in chronic‑disease management.
Comments
Want to join the conversation?
Loading comments...